Does powerful editing tool CRISPR really help treat diseases? There are a lot of pharmaceutical companies racing to find the answers.
Recently, Bayer AG announced a joint venture with startups CRISPR Therapeutics for the treatment of three hundred million US dollars to develop drugs for blood disorders, blindness, congenital heart diseases. This is just the pharmaceutical industry eager to take advantage of the first signs of CRISPR find and develop new methods of treatment. However, fully grasp the CRISPR tool to develop the full potential of the drug is still too early, will focus on recent developments in the CRISP system uses to edit specific condition to go.
CRISPR Therapeutics is one of three high-profile start-up companies, the other two are Editas Medicine and Intellia Therapeutics. They hope to use CRISPR gene editing tools to develop new drugs. All three companies are working with a large pharmaceutical manufacturing company has won or investment transactions in the past year has revealed broad areas of disease drug manufacturers see opportunities for the application of new tools.
In the short term, CRISPR's use in some genetic diseases or cancer cases may be more attractive. These therapies mean removing the body cells, modifying their DNA, and reintroducing them. However, the three companies are also interested in the development of technology to deliver CRISPR cells in the body, without removing it. This will be a more complex challenge.
A major goal of Bayer and CRISPR Therapeutics create the joint venture is to develop new transmission technology, which is the future of drug development in vivo cell is the "key", Rodger Novak, CEO of CRISPR Therapeutics. This is not a small challenge. In order to work, the drug must first find a suitable organ or tissue. Once it's there, it must be a safe way to put payloads into the correct cells.
You may like to read this: http://www.cusabio.com/ELISA-Kit/Goat-vitamin-B12-VB12-ELISA-kit-1042287.html
没有评论:
发表评论